NovaBay to Hold Conference Call to Review Aganocide Data Presented at the Infectious Diseases Society of America Meeting

Call to Include Review of NovaBay Clinical Development Program Progress

• Press Release
• Source: NovaBay Pharmaceuticals, Inc.
• On 7:30 am EDT, Wednesday October 28, 2009

EMERYVILLE, Calif., Oct. 28 /PRNewswire-FirstCall/ -- NovaBay Pharmaceuticals, Inc. (NYSE-Amex: NBY) will hold a webcast conference call on October 30, 2009 to review preclinical data from a study of Aganocide® product candidates NVC-422 and NVC-612 in a model of onychomycosis, commonly termed nail fungus. The study data will be presented on October 31, 2009 in Philadelphia, PA at the 47th Annual Meeting of the Infectious Diseases Society of America. During the conference call, Dr. Ron Najafi, chairman and chief executive officer and Dr. Behzad Khosrovi, senior vice president of product development, both of NovaBay, will also provide a brief update of the Company's clinical progress and corporate development efforts.

    Conference call information:
    Date/time of live call: Friday October 30, 2009, 10:00 AM eastern time
    US/Canada dial-in: (877) 862-4241 / international dial-in: (281) 312-0948
    US/Canada replay: (800) 642-1687 / international replay: (706) 645-9291
    Passcode for live and archived conference call is 37797881

For the live and archived webcast, please visit the Investor Events page on the NovaBay website at www.novabaypharma.com. The webcast will be archived for 90 days and the telephone replay for seven days.

The poster to be presented at the Annual Meeting of the Infectious Diseases Society of America is titled "In Vitro Evaluation of Stable Derivatives of the Chlorotaurines on Infected Human Nail Model as Potent Antifungal Agents for the Treatment of Onychomycosis" and may be found on the NovaBay website on the NovaBay Publications page under Technology on or about October 31, 2009.

About NovaBay

NovaBay Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing its proprietary and patented Aganocide compounds, which are novel, synthetic anti-infective product candidates that are bioequivalent to the active antimicrobial molecules generated within white blood cells to treat and prevent a wide range of infections without causing bacterial resistance. NovaBay has internal development programs aimed at addressing hospital and respiratory infections. The company has a licensing and research collaboration agreement with Alcon, Inc. for use of its Aganocide compounds to treat eye, ear and sinus infections as well as in contact lens care solutions. NovaBay has also entered into an agreement with Galderma S.A. to develop and commercialize Aganocides in acne, impetigo and other dermatological indications. NovaBay® and Aganocide® are trademarks of NovaBay Pharmaceuticals, Inc. For more information on NovaBay, visit: www.novabaypharma.com.

Buzz up!